JP6383151B2 - 脳損傷治療用step誘導ペプチド - Google Patents
脳損傷治療用step誘導ペプチド Download PDFInfo
- Publication number
- JP6383151B2 JP6383151B2 JP2013529343A JP2013529343A JP6383151B2 JP 6383151 B2 JP6383151 B2 JP 6383151B2 JP 2013529343 A JP2013529343 A JP 2013529343A JP 2013529343 A JP2013529343 A JP 2013529343A JP 6383151 B2 JP6383151 B2 JP 6383151B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide according
- domain
- derived peptide
- residue
- numbering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Description
本発明はNINDSによって認可された政府支援5R01NS059962−04に関する発明である。米国政府は、本発明に関し、一定の権利を有する。
関連出願に関する相互参照
配列リスト
(90分間中位大脳動脈閉塞により塞栓症発作を発症させた後に24時間再灌流処置する)脳虚血症の動物モデルを使用して、活性STEPの減成がニューロン細胞死および引き続き生じる脳損傷に寄与するかどうか、そして修飾STEPペプチドが虚血性脳損傷を緩和できるかどうかを評価した。まず、STEPの活性化、引き続き生じる減成、その後の脳虚血症および再灌流の時間的なプロファイルを調べ、これらのp38MAPK活性化との相関関係を評価した。虚血性損傷後15分経たないうちにp38MAPKのリン酸化に急激ではあるが遷移的な増加が認められた。その後、30分経過から時間が経つにつれてp38リン酸化が減少し、90分までに基底レベルに戻った。この虚血性損傷の結果、p38MAPKが急激に活性化するだけではなく、STEPの脱リン酸化および引き続き生じる活性化が生じ、これは30分で開始し、90分までに完全な脱リン酸化が生じた。この結果、活性STEPがp38MAPKの活性化持続時間を制限することになる。減成による活性STEPの進行的な下方調節は、p38MAPKの二次活性化に結果する再灌流後〜6時間目から明らかになる。p38MAPK経路の一次的ではないが二次的な活性化は、p38MAPKの活性化にリンクし、かつ炎症反応および反応性酸素種の発生に関与する(発表原稿は準備中)主要酵素であるシクロオキシゲナーゼ−2(COX−2)の発現と相関関係にある。以上の知見は、本発明の仮説に一致し、STEPが細胞死経路のネガティブな調節体であり、活性STEPの減成が信号カスケードをトリガーし、虚血性脳損傷につながることを示している。
Claims (14)
- STEPタンパク質のKIMドメインおよびKISドメインを具備してなるSTEP誘導ペプチドであり、前記KIMドメインのセリン49残基を非リン酸化性アミノ酸に変換させて易リン酸化部位のリン酸化を防止することでペプチドのSTEP活性を活性化し、同時に、前記KISドメインのスレオニン59残基および/またはセリン72残基を模倣リン酸化性アミノ酸に変換させて内因性STEPタンパク質よりも安定なペプチドとすることを特徴とする、STEP誘導ペプチド(各残基はSTEP 46 変異型からの番号付け(numbering)を用いる)。
- 前記KIMドメインの前記セリン49残基(前記STEP46変異型からの番号付け(numbering)を用いて)がアラニンに変換されている請求項1に記載のSTEP誘導ペプチド。
- 前記KISドメインの前記セリン72残基(前記STEP46変異型からの番号付け(numbering)を用いて)が模倣リン酸化性アミノ酸に変換されている請求項1又は2に記載のSTEP誘導ペプチド。
- 前記KISドメインの前記スレオニン59残基(前記STEP46変異型からの番号付け(numbering)を用いて)が模倣リン酸化性アミノ酸に変換されている請求項1又は2に記載のSTEP誘導ペプチド。
- 前記KISドメインの前記セリン72残基(前記STEP46変異型からの番号付け(numbering)を用いて)および前記スレオニン59残基(前記STEP46変異型からの番号付け(numbering)を用いて)の双方が模倣リン酸化性アミノ酸に変換されている請求項1又は2に記載のSTEP誘導ペプチド。
- 前記模倣リン酸化性アミノ酸がグルタミン酸残基又はアスパラギン酸残基である請求項1、2、3、4又は5に記載のSTEP誘導ペプチド。
- 前記模倣リン酸化性アミノ酸がグルタミン酸残基である請求項1、2、3、4、5又は6に記載のSTEP誘導ペプチド。
- Cys23残基(前記STEP46変異型からの番号付け(numbering)を用いて)がアラニンに変換されたものである請求項1、2、3、4、5、6又は7に記載のSTEP誘導ペプチド。
- 前記ペプチドの1領域が細胞透過性となるようにさらに構成されている請求項1、2、3、4、5、6、7又は8に記載のSTEP誘導ペプチド。
- 細胞透過性となるように構成された前記ペプチドの前記1領域がTATドメインである請求項9に記載のSTEP誘導ペプチド。
- 観察可能なマーカーとして作用するように構成された領域をさらに有する請求項1、2、3、4、5、6、7、8、9又は10に記載のSTEP誘導ペプチド。
- 観察可能なマーカーとして作用するように構成された前記領域がmyc領域である請求項11に記載のSTEP誘導ペプチド。
- SEQ ID.No.4,8,10または11からなる群から選択される請求項1に記載のSTEP誘導ペプチド。
- 過剰なグルタメートの作用から発症する脳損傷の作用を治療または緩和するために使用され、静脈注射により患者に送り込まれる請求項1〜13のいずれか1項に記載のSTEP誘導ペプチド。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38320810P | 2010-09-15 | 2010-09-15 | |
US61/383,208 | 2010-09-15 | ||
PCT/US2011/051827 WO2012037397A2 (en) | 2010-09-15 | 2011-09-15 | Step-derived peptide for brain injury treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014505010A JP2014505010A (ja) | 2014-02-27 |
JP2014505010A5 JP2014505010A5 (ja) | 2014-10-16 |
JP6383151B2 true JP6383151B2 (ja) | 2018-08-29 |
Family
ID=45832252
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013529343A Expired - Fee Related JP6383151B2 (ja) | 2010-09-15 | 2011-09-15 | 脳損傷治療用step誘導ペプチド |
Country Status (5)
Country | Link |
---|---|
US (3) | US9068172B2 (ja) |
EP (1) | EP2616485A4 (ja) |
JP (1) | JP6383151B2 (ja) |
CA (1) | CA2811086C (ja) |
WO (1) | WO2012037397A2 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012037397A2 (en) * | 2010-09-15 | 2012-03-22 | Stc.Unm | Step-derived peptide for brain injury treatment |
GB201314610D0 (en) * | 2013-08-15 | 2013-10-02 | Blueberry Therapeutics Ltd | Compounds and their uses |
WO2021155354A1 (en) * | 2020-01-31 | 2021-08-05 | Unm Rainforest Innovations | Regulation of post-ischemic inflammatory response |
RO135590A1 (ro) | 2020-08-31 | 2022-03-30 | Szedlacsek Ştefan Eugen | Peptide de interferenţă ca inhibitori ai interacţiunilor legate de endocitoza receptorilor ampa |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6015834A (en) | 1992-10-20 | 2000-01-18 | Toronto Neuroprotection Group | In vivo treatment of mammalian cells with a cell membrane permeant calcium buffer |
AU2003247143B2 (en) | 2002-08-01 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels |
WO2005055813A2 (en) | 2003-12-08 | 2005-06-23 | Agy Therapeutics, Inc. | Interaction of nmda receptor with the protein tyrosine phosphatase step in psychotic disorders |
EP2007206A4 (en) | 2006-03-16 | 2010-12-08 | Yeda Res & Dev | METHOD AND COMPOSITION FOR THE PROTECTION OF NEURONAL TISSUE FROM DEGATES INDUCED BY HIGH LEVELS OF GLUTAMATE |
US20090004112A1 (en) | 2006-04-21 | 2009-01-01 | The Trustees Of Columbia University In The City Of New York | Methods for the treatment of neurodegenerative diseases using nmda receptor glycine site antagonists |
KR100999043B1 (ko) * | 2007-12-04 | 2010-12-09 | 한국생명공학연구원 | 융합 단백질을 사용하지 않는 인간 단백질 타이로신탈인산화 효소의 활성 도메인 대량 생산 방법 |
WO2009099563A2 (en) | 2008-02-05 | 2009-08-13 | Blanchette Rockefeller Neurosciences Institute | Combination of a nmda receptor channel blocker and a pkc activator for treatment of alzheimer's disease |
WO2012037397A2 (en) * | 2010-09-15 | 2012-03-22 | Stc.Unm | Step-derived peptide for brain injury treatment |
-
2011
- 2011-09-15 WO PCT/US2011/051827 patent/WO2012037397A2/en active Application Filing
- 2011-09-15 EP EP11825972.0A patent/EP2616485A4/en not_active Withdrawn
- 2011-09-15 JP JP2013529343A patent/JP6383151B2/ja not_active Expired - Fee Related
- 2011-09-15 CA CA2811086A patent/CA2811086C/en not_active Expired - Fee Related
- 2011-09-15 US US13/823,856 patent/US9068172B2/en active Active
-
2015
- 2015-05-26 US US14/721,024 patent/US10087429B2/en active Active
-
2018
- 2018-08-29 US US16/116,117 patent/US10570381B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
JP2014505010A (ja) | 2014-02-27 |
US9068172B2 (en) | 2015-06-30 |
CA2811086C (en) | 2020-07-21 |
US20190169583A1 (en) | 2019-06-06 |
US10087429B2 (en) | 2018-10-02 |
CA2811086A1 (en) | 2012-03-22 |
US10570381B2 (en) | 2020-02-25 |
EP2616485A2 (en) | 2013-07-24 |
WO2012037397A3 (en) | 2012-06-28 |
US20140170130A1 (en) | 2014-06-19 |
WO2012037397A2 (en) | 2012-03-22 |
EP2616485A4 (en) | 2014-04-02 |
US20150252339A1 (en) | 2015-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Goebel-Goody et al. | Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders | |
US10570381B2 (en) | STEP-derived peptide for brain injury treatment | |
Beurdeley et al. | Otx2 binding to perineuronal nets persistently regulates plasticity in the mature visual cortex | |
Schnizler et al. | Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons | |
Kostenko et al. | Heat shock protein 27 phosphorylation: kinases, phosphatases, functions and pathology | |
US9107868B2 (en) | Neuronal pain pathway | |
Yamamoto et al. | Chemical physiology of oxidative stress-activated TRPM2 and TRPC5 channels | |
Jiang et al. | Interaction of α carboxyl terminus 1 peptide with the connexin 43 carboxyl terminus preserves left ventricular function after ischemia‐reperfusion injury | |
Reverte-Salisa et al. | Role of cAMP and cGMP signaling in brown fat | |
Zhang et al. | Unfolded protein response as a therapeutic target in cardiovascular disease | |
Li et al. | BDNF contributes to spinal long-term potentiation and mechanical hypersensitivity via Fyn-mediated phosphorylation of NMDA receptor GluN2B subunit at tyrosine 1472 in rats following spinal nerve ligation | |
Salter et al. | Regulation of NMDA receptors by kinases and phosphatases | |
JP6177769B2 (ja) | シータデフェンシンによる炎症性プロテアーゼの遮断 | |
Palazzo et al. | Nociception modulation by supraspinal group III metabotropic glutamate receptors | |
JP2012524112A (ja) | 統合失調症および双極性障害を治療するための組織カリクレイン | |
Lazarev et al. | Factors affecting aggregate formation in cell models of Huntington’s disease and amyotrophic lateral sclerosis | |
Chen et al. | Insulin stimulates increased catalytic activity of phosphoinositide-dependent kinase-1 by a phosphorylation-dependent mechanism | |
He et al. | Spinal and afferent PKC signaling mechanisms that mediate chronic pain in sickle cell disease | |
Nury et al. | Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting | |
Peng et al. | Hydrogen sulfide upregulates acid-sensing ion channels via the MAPK-Erk1/2 signaling pathway | |
CN103804500A (zh) | 用于治疗慢性疼痛的多肽 | |
Cruz-Torres | Modifications to TRPM2 channel activity following global cerebral ischemia | |
Cattelan et al. | HIV-1 TAT-mediated protein transduction of human HPRT into deficient cells | |
Nagy et al. | Molecular mechanisms of TRPV1-mediated pain | |
Tasdemiroglu et al. | Degradation of the α-Carboxyl Terminus 11 Peptide: In Vivo and Ex Vivo Impacts of Time, Temperature, Inhibitors, and Gender in Rat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140304 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140829 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140829 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151117 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160212 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160314 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160415 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160516 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161108 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170309 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170316 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170519 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180517 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180803 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6383151 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |